Home › Pharmacology › Systemic Sulfonamides

Systemic Sulfonamides

Sulfanilamides

For medical students2 min readUpdated 2026-10-10

Systemic sulfonamides are a group of antibacterial agents used to treat a wide range of infectious diseases. Long-acting drugs in this class are characterized by convenient dosing regimens and extremely slow elimination from the body, making them effective for both acute and protracted chronic conditions.

AdministrationMost drugs in this group are prescribed only once daily

EliminationVery slow due to intensive tubular reabsorption

ComplicationsHigh risk of severe Stevens-Johnson syndrome

SpectrumFrom routine bronchitis to drug-resistant malaria

Clinical Application and Spectrum of Activity

In clinical practice, long-acting systemic sulfonamides hold an important place due to their broad coverage of infectious pathologies. A clinician may choose these drugs in the treatment of various inflammatory processes.

First, these include purulent-inflammatory lesions of the skin and underlying soft tissues. The drugs show high effectiveness when dealing with severe, slow-healing wounds and ulcers. They are also indicated for the treatment of pressure ulcers in bedridden patients, abscesses, and furuncles.

Second, respiratory tract infections are a target for this group. This includes both inflammation of the bronchial tree (bronchitis) and pulmonary parenchymal involvement (pneumonia).

Third, the drugs successfully combat lower urinary tract infections.

Special attention is warranted for their use in specific and hard-to-treat infections. This list includes:

Gonorrhea;
Trachoma (infectious eye disease);
Purulent meningitis;
Drug-resistant malaria (when standard treatment regimens prove ineffective).

Pharmacokinetics: Why Do They Act for So Long?

It is crucial for students to understand the pharmacokinetic mechanisms responsible for the prolonged effect of these medications. The main characteristic of long-acting drugs is their very slow elimination from the patient's body.

Why does this happen? The answer lies in the function of the urinary system. After the drug passes through the renal glomeruli, it enters the renal tubule system. It is here that intensive reabsorption takes place—the process of active uptake of the active substance molecules from the primary urine back into the systemic circulation.

Due to this pronounced tubular reabsorption, the concentration of the drug in the blood decreases extremely slowly. This directly affects the dosing regimen: unlike short-acting drugs, long-acting systemic sulfonamides in most cases need to be administered only once daily. This significantly improves patient adherence to the prescribed therapy.

Specific Drug Review: Sulfalene

To understand clinical nuances, let us examine sulfalene (Sulfalenum) in detail. Its use requires the clinician to clearly understand the stage and nature of the disease, as the dosing regimen changes cardinally depending on the situation.

If a patient is suffering from an acute, rapidly progressing infection, sulfalene is prescribed for daily administration. This allows for the rapid creation and maintenance of a high therapeutic concentration at the site of inflammation.

A completely different tactic is used for chronic, protracted infectious processes. In this case, the pharmacokinetics of the drug is fully realized:

When taken orally (enteral administration), it is sufficient to administer the drug only once every 7–10 days.
With parenteral administration (intramuscular or intravenous injections), the drug is administered once daily.

However, the use of sulfalene requires strict vigilance regarding side effects. The most dangerous complication is the development of a severe allergic reaction—Stevens-Johnson syndrome. The physician must warn the patient about potential skin manifestations and immediately discontinue therapy at the first signs of allergy.

Mnemonic

To remember the characteristics of sulfalene, use the association: "Acute — every day, Chronic — once a week." And slow elimination is easily linked to "greedy kidneys" that actively return the drug to the blood (reabsorption).

Frequently asked questions

What is the mechanism of antibacterial action of sulfonamides?

The mechanism of antibacterial action of sulfonamides is the competitive inhibition of the enzyme dihydropteroate synthase. Being structural analogs of para-aminobenzoic acid (PABA), the drugs enter into competitive antagonism with it at the earliest stage of synthesis. This leads to the blockade of dihydropteroic and dihydrofolic acid formation. As a result, the synthesis of folic acid is disrupted, which serves as a precursor for purine and pyrimidine bases, ultimately blocking nucleic acid synthesis in the bacterial cell.

Which drugs belong to the group of long-acting and ultra-long-acting sulfonamides?

The group of long-acting and ultra-long-acting sulfonamides includes drugs used for purulent-inflammatory diseases.

Main representatives include:

Sulfamethoxypyridazine — a long-acting drug.
Sulfadimethoxine — a long-acting drug.
Sulfalene — an ultra-long-acting drug.

Sulfalene is characterized by very slow elimination from the body, due to its intensive reabsorption in the renal tubules. Because of this, in chronic infections, it can be administered orally only once every 7–10 days.

What side effects are characteristic of systemic sulfonamides?

Systemic sulfonamides are characterized by various allergic reactions, organotoxicity, and systemic disorders.

Main side effects include:

Allergic reactions — rash, photosensitization, severe Stevens-Johnson syndrome.
Gastrointestinal tract — dyspeptic disorders.
Liver — hepatotoxicity.
Hematopoiesis — anemia, leukopenia, thrombocytopenia.
Kidneys — crystalluria (precipitation of crystals in acidic urine).
Central nervous system — kernicterus in newborns due to displacement of bilirubin from binding to albumin.

What is the spectrum of antimicrobial activity of sulfonamides, indicating specific microorganisms?

The spectrum of antimicrobial activity of sulfonamides initially included Gram-positive and Gram-negative flora, but widespread acquired resistance is now observed.

The drugs retain activity against the following microorganisms:

Nocardia — specific pathogens.
Toxoplasma — specific pathogens.
Chlamydia — specific pathogens.
Pneumocystis — specific pathogens.
Malarial plasmodia — specific pathogens.
Actinomycetes — specific pathogens.
Escherichia coli — suppressed by drugs acting within the intestinal lumen.

What are the absolute contraindications to the use of systemic sulfonamides?

Contraindications and limitations for the use of systemic sulfonamides include:

Pronounced liver and kidney dysfunction.
Hematopoietic disorders.
Pregnancy — listed in some sources as a contraindication; another source clarifies that sulfonamides belong to Category C, except in late pregnancy, where they are Category D.
Newborns — sulfonamides are contraindicated due to the risk of kernicterus: the drugs displace bilirubin from binding to albumin, increasing free bilirubin concentration and the risk of toxic brain damage.
Hypersensitivity — listed as a general contraindication for antibacterial drugs.

With which drug groups do sulfonamides exhibit clinically significant antagonism?

Sulfonamides exhibit clinically significant chemical antagonism with local anesthetics that are derivatives of esters of para-aminobenzoic acid (PABA).

Such drugs include:

Procaine (novocaine) — a local anesthetic.
Benzocaine — a local anesthetic.

During the hydrolysis of these medications in the body, PABA is released. It acts as a competitive antagonist of sulfonamides, which ultimately neutralizes and significantly weakens their antimicrobial effect.

Why are long-acting systemic sulfonamides taken so infrequently?

This is due to their pharmacokinetics. Intensive reabsorption (backward transport) of the drug occurs in the renal tubules, causing it to be eliminated from the body very slowly and circulate in the blood for a long time.

How does the dosage of sulfalene change when an infection transitions to a chronic form?

In chronic and protracted infections, oral administration of sulfalene is reduced to once every 7–10 days. However, if the drug is administered parenterally (intravenously or intramuscularly), injections continue to be given once daily.

What formidable complication should be anticipated when prescribing sulfalene?

The main danger is the risk of developing Stevens-Johnson syndrome. This is a severe allergic reaction requiring immediate discontinuation of the drug and medical intervention.

In which specific infections is the prescription of these drugs justified?

They are highly effective in treating gonorrhea, trachoma, purulent meningitis, and are successfully used in treatment regimens for drug-resistant malaria.

Go deeper

Mechanism of tubular reabsorption of sulfonamides at the cellular level
Pathogenesis and clinical presentation of Stevens-Johnson syndrome
Combination therapy regimens for drug-resistant malaria
Pharmacokinetic differences between oral and parenteral administration of sulfalene
Principles of comprehensive treatment for slow-healing ulcers and pressure sores